Effect of cerebral small vessel disease on the integrity of cholinergic system in mild cognitive impairment patients: a longitudinal study Tiantian QiuHui Hongfor the Alzheimer’s Disease Neuroimaging Initiative Original Communication Open access 21 February 2024 Pages: 2704 - 2715
Real-word application of the AT(N) classification and disease-modifying treatment eligibility in a hospital-based cohort Elisa CanuGiulia RugarliFederica Agosta Original Communication 21 February 2024 Pages: 2716 - 2729
Increased incidence of motor neuron disease in Sweden: a population-based study during 2002–2021 Sofia ImrellFang FangStefan Sennfält Original Communication Open access 22 February 2024 Pages: 2730 - 2735
Different pain phenotypes are associated with anti-Caspr2 autoantibodies Patrik GreguletzMaria Plötzthe GENERATE study group Original Communication Open access 22 February 2024 Pages: 2736 - 2744
Risk and sex-specific trends of dementia and stroke in Italy Compared to European and high-income countries and the world: global implications Abolfazl AvanAntonia NuceraVladimir Hachinski Original Communication 23 February 2024 Pages: 2745 - 2757
Improvement of fatigue in generalised myasthenia gravis with zilucoplan Michael D. WeissMiriam FreimerJames F. Howard Jr Original Communication Open access 24 February 2024 Pages: 2758 - 2767
Serum neurofilament light chain associates with symptom burden in Lyme neuroborreliosis patients: a longitudinal cohort study from Norway Ingerid SkarsteinElling UlvestadSteffan Daniel Bos Original Communication Open access 26 February 2024 Pages: 2768 - 2775
Don’t delay, but don’t despair: symptom duration, comorbidity and outcome after closure of spinal cerebrospinal fluid leaks Florian VolzAmir El RahalKatharina Wolf Original Communication Open access 26 February 2024 Pages: 2776 - 2786
5qSMA: standardised retrospective natural history assessment in 268 patients with four copies of SMN2 Katharina VillMoritz TackeSMArtCARE study group Original Communication Open access 27 February 2024 Pages: 2787 - 2797
Anatomical correlates of apathy and impulsivity co-occurrence in early Parkinson’s disease Gianpaolo MaggiFrancis LoayzaIgnacio Obeso Original Communication Open access 28 February 2024 Pages: 2798 - 2809
104-week efficacy and safety of cipaglucosidase alfa plus miglustat in adults with late-onset Pompe disease: a phase III open-label extension study (ATB200-07) Benedikt SchoserPriya S. Kishnanithe ATB200-07 Study Group Original Communication Open access 28 February 2024 Pages: 2810 - 2823
Burden of disease in Lambert-Eaton myasthenic syndrome: taking the patient’s perspective Sophie LehnererMeret HerdickAndreas Meisel Original Communication Open access 29 February 2024 Pages: 2824 - 2839
MOG-IgG testing strategies in accordance with the 2023 MOGAD criteria: a clinical-laboratory assessment Mario RisiGiacomo GrecoMatteo Gastaldi Short Commentary 27 January 2024 Pages: 2840 - 2843
Midbrain lesion-induced disconjugate gaze: a unifying circuit mechanism of ocular alignment? Maximilian U. FriedrichLaurin SchappeKlaus-Ulrich Dillmann Short Commentary Open access 14 February 2024 Pages: 2844 - 2849
Patient acceptance of teleneurology across neurologic conditions Courtney R. SeigelHolly MartinLinda S. Williams Short Commentary Open access 23 February 2024 Pages: 2850 - 2858
CHD8-related disorders redefined: an expanding spectrum of dystonic phenotypes Ugo SorrentinoSylvia BoeschMichael Zech Short Commentary Open access 05 March 2024 Pages: 2859 - 2865
Newly emerging type B insulin resistance (TBIR) during treatment with eculizumab for AQP4-IgG-positive neuromyelitis optica spectrum disorder (NMOSD): fatal outcome S. DoubrovinskajaM. Korporal-KuhnkeB. Wildemann Letter to the Editors Open access 14 November 2023 Pages: 2866 - 2870
Humoral response after accelerated schedule of HBV vaccination in MS patients before anti-CD20 therapy Elisabeth MaillartEve TodescoValérie Pourcher Letter to the Editors 11 January 2024 Pages: 2871 - 2874
POLAR: prediction of prolonged mechanical ventilation in patients with myasthenic crisis Dominik HeiderHenning StetefeldThe German Myasthenic Crisis Study Group Letter to the Editors Open access 08 February 2024 Pages: 2875 - 2879
Inflammatory neuropathy with evidence of anti-GQ1b antibodies in angioimmunoblastic T cell lymphoma (AITL): a case report Antonia KleebergGregor BauerJan C. Purrucker Letter to the Editors Open access 08 February 2024 Pages: 2880 - 2885
RFC1 repeat expansions in downbeat nystagmus syndromes: frequency and phenotypic profile David PellerinFelix HeindlMatthis Synofzik Letter to the Editors Open access 21 February 2024 Pages: 2886 - 2892
Familial hemophagocytic lymphohistiocytosis: from macrophage activation syndrome to CLIPPERS Bruno LemarchantGeneviève de Saint BasileGuillaume Taieb Letter to the Editors 21 February 2024 Pages: 2893 - 2897
Ravulizumab in myasthenic crisis: the first case report Franz Felix KonenKonstantin Fritz JendretzkyThomas Skripuletz Letter to the Editors Open access 23 February 2024 Pages: 2898 - 2901
Dramatic improvement in refractory myasthenia gravis with eculizumab treatment: a case report Kana OhnariTomoyo HashimotoKazumasa Okada Letter to the Editors 23 February 2024 Pages: 2902 - 2905
Primary central nervous system lymphoma Myrthe E. de KoningJurrit J. HofMatthijs van der Meulen Neurological Update 19 December 2023 Pages: 2906 - 2913
Amyloid antibody therapy for early-stage Alzheimer’s disease: a critical review of three recent trials A. E. GuiloffP. Rudge Journal club Open access 13 April 2024 Pages: 2914 - 2916
Louis Jacobsohn-Lask (1863–1940) Ibrahim DemircubukEsra CandarGulgun Sengul Pioneers in Neurology Open access 06 March 2024 Pages: 2919 - 2921
Alfred A. Strauss (1897–1957) Lawrence A. Zeidman Pioneers in Neurology 26 March 2024 Pages: 2922 - 2924
Correction to: The impact of metformin use on the outcomes of relapse‑remitting multiple sclerosis patients receiving interferon beta 1a: an exploratory prospective phase II open‑label randomized controlled trial Mohamed Y. AbdelgaiedMohamed Hamed RashadMohamed H. Solayman Correction 18 March 2024 Pages: 2925 - 2925
Correction to: Neurofilament light in plasma is a potential biomarker of central nervous system involvement in systemic lupus erythematosus Maria Boge LauvsnesHenrik ZetterbergRoald Omdal Correction 23 March 2024 Pages: 2926 - 2927